Author

Angela George

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genetics· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:benchmarking· 2 Assay:DNA methylation· 2 Approach:statistical model· 2 Assay:whole-genome sequencing· 2 Approach:experimental assay· 1 Research Focus:variant calling· 1

Frequent Co-Authors

Ann Strydom· 3 shared Nazneen RahmaniD· 3 shared Helen Hanson· 2 shared Ingrid Slade· 2 shared Anthony Bentley· 1 shared Anthony Eccleston· 1 shared Daniel Riddell· 1 shared Elise RuarkiD· 1 shared

Activity by Year

2016-2016 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersGenetics

Ann Strydom

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A discrete event simulation to evaluate the cost effectiveness of germline BRCA1 and BRCA2 testing in UK women with ovarian cancer

Anthony Eccleston, Anthony Bentley, Matthew Dyer, Ann Strydom, Wim Vereecken, Angela George, Nazneen Rahman

This study evaluates the cost-effectiveness of germline BRCA testing in UK ovarian cancer patients, finding it cost-effective with an ICER of £4,339/QALY.

bioRxiv · Jun 24, 2016 · PreprintGenetics

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients

Angela George, Daniel Riddell, Sheila Seal, Sabrina Talukdar, Shazia Mahamdallie, Elise Ruark, Victoria Cloke, Ingrid Slade, Zoe Kemp, Martin Gore, Ann Strydom, Susana Banerjee, Helen Hanson, Nazneen Rahman, Mainstreaming Cancer Genetics (MCG) Programme

This study implements a streamlined BRCA gene testing pathway for ovarian cancer patients, achieving high uptake and efficiency with significant cost savings and improved patient outcomes.

bioRxiv · Mar 16, 2016Genetics

A cost analysis of a cancer genetic service model in the UK

Ingrid Slade, Helen Hanson, Angela George, Kelly Kohut, Ann Strydom, Sarah Wordsworth, Nazneen Rahman, MCG Programme

This paper analyzes the costs of BRCA gene testing pathways in a UK cancer genetics service, finding significant cost variation and suggesting cost-efficiency improvements by testing more cancer patients.

Journal of Community Genetics · Feb 27, 2016Peer-reviewedGenetics